Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of Ultherapy PRIME – a noninvasive treatment that provides a truly personalized and long-lasting* lift of the skin in one session with zero downtime.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240923820281/en/
Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments (Photo: Business Wire)
The Ultherapy PRIME platform is the evolution of Ultherapy®, which has been recognized as the Gold Standard for nonsurgical lifting and skin tightening due to its large body of clinical evidence, well-established mechanism of action (MOA) and high patient satisfaction.1,2,3 Built on a legacy of proven, natural-looking outcomes, Ultherapy PRIME redefines the future of non-invasive skin lifting and tightening by uniquely combining advanced ultrasound technology, vivid real-time imaging and proven results. These advancements promote long-lasting* results paired with healthier-looking skin.1,2,3,4,5
The platform features a modern design with an advanced operating system, delivering 10x faster processing power, elevated ergonomics and seamless workflows for aesthetic health care professionals. Additionally, with a 35% larger screen and brighter, crisp images from all angles, Ultherapy PRIME offers a vivid visualization experience for a truly personalized, long-lasting* lift patients can see.**
“The launch of Ultherapy PRIME demonstrates our commitment to persist in innovation,” said Bob Rhatigan, CEO, Merz Aesthetics. “As the leader in noninvasive lifting, we’re excited to bring Ultherapy PRIME to our customers as the next generation, premier platform and as a proven technology*** and customizable, long-lasting* treatment option.”
Ultherapy PRIME’s unique technology with real-time visualization goes beyond other noninvasive treatments to target the right collagen and elastin-rich layers of the tissue at multiple depths, delivering consistent and precise energy where the patient needs it the most.1,2,3,4,6,7 Ultherapy PRIME’s mechanism of action allows for personalized skin lifting outcomes through collagen and elastin stimulation, which can last up to a year or more.1,2,3,4,6,7 It is a great treatment option for all skin types and skin tones to maintain a youthful, healthy appearance in just one session with zero downtime.1
With three million Ultherapy treatments performed around the world, Ultherapy PRIME builds on an impressive legacy of lifts of the skin on the brows, area under the chin and neck and improves lines and wrinkles on the décolleté.1,2,3 With Ultherapy’s 95% patient satisfaction at year one and one of the strongest clinical bodies of evidence cited in over 120 publications and 56 clinical studies,2,4 Ultherapy PRIME is built on a legacy of safe and effective treatments. Ultherapy PRIME is The Lift You Can SEE.
“Now more than ever, patients seek treatments tailored to their unique skin needs. This is why Ultherapy is a cornerstone of my practice,” said world-renowned, board-certified dermatologist Sabrina Fabi, MD. “The new Ultherapy PRIME platform offers all the signature benefits of Ultherapy for noninvasive, long-lasting* lifting, now with significant advancements. Ultherapy PRIME improves the quality of the skin, catering to diverse patient needs with all skin types seeking a noninvasive lift and a younger, healthier appearance in just one session and no downtime.”
To learn more about Ultherapy PRIME, visit Ultherapy.com and follow @Ultherapy on Instagram.
*results can last up to a year or more 1,4
** in comparison to the previous version
***based on clinical studies conducted with Ultherapy legacy device
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
About Ultherapy®:
The noninvasive Ultherapy® procedure is intended for dermatological sculpting and lifting of the dermis on the upper face, lower face, neck and décolleté. The most common side effects reported in clinical trials were redness, swelling, pain and transient nerve effects. Reported adverse events from post-marketing surveillance are available in the Instructions for Use (IFU). Please see the IFU for product information.
References:
- Ulthera® Instructions for Use
- Fabi SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432.
- Park JY, et al. Customized Treatment Using Microfocused Ultrasound with Visualization for Optimized Patient Outcomes: A Review of Skin tightening Energy Technologies and a Pan-Asian Adaptation of the Expert Panel’s Gold Standard Consensus. J Clin Aesthet Dermatol. 2021;14(5): E70-E79.
- Werschler WP, Werschler PS. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
- Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality - A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518.
- Sasaki G, Grossman J, Fabi SG, et al. Stimulation of Collagen Synthesis in Human Skin Following Microfocused Ultrasound Therapy. Presented at the ASDS 2018 Annual Meeting.
- White WM, Makin IR, Barthe PG, Slayton MN, Gliklich RE. Selective creation of thermal injury zones in the superficial musculoaponeurotic system using intense ultrasound therapy: a new target for non-invasive facial rejuvenation. Arch Facial Plast Surg. 2007;9(1):22-29.
© 2024 Merz North America, Inc., Merz, and Merz Aesthetics are trademarks or registered trademarks of Merz Pharma GmbH & Co. KGaA in the EU and/or certain other countries. Ultherapy, Ulthera are trademarks and/or registered trademarks of Ulthera, Inc. in the EU and/or certain other countries. Various features of the ULTHERA® System are covered by U.S. patents identified at https://merzaesthetics.com/patents/. Other U.S. and International patents to which Ulthera, Inc. has rights are issued, published, or pending.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923820281/en/
Contacts
Emily Browder
Head of Global Communications
6501 Six Forks Road Raleigh NC 27615
919-302-3296
media@merz.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press Release
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c
BitGo yn Sicrhau Cymeradwyaeth OCC i Drosi i Fanc Ymddiriedolaeth Genedlaethol Siartredig Ffederal13.12.2025 02:13:00 CET | Pressmeddelande
Cyhoeddodd BitGo Holdings, Inc. (“BitGo”), y cwmni seilwaith asedau digidol, heddiw fod Swyddfa Rheolwr yr Arian Cyfred (“OCC”) wedi cymeradwyo ei gais i drosi BitGo Trust Company, Inc., cwmni ymddiriedolaeth siartredig De Dakota, i fanc cenedlaethol o'r enw BitGo Bank & Trust, National Association (N.A.). Gyda chymeradwyaeth OCC heddiw o'i drosi, mae is-gwmni Cwmni Ymddiriedolaeth BitGo bellach yn gweithredu fel BitGo Bank & Trust, National Association (N.A.). Bydd BitGo Bank & Trust, N.A. yn gweithredu o dan un gyfundrefn oruchwylio ffederal unffurf, gan ei alluogi i ddarparu'r eglurder, y llywodraethiant, a'r sicrwydd rheoleiddiol y mae sefydliadau'n eu disgwyl gan ymddiriedolwr a reoleiddir yn ffederal. Mae'r gymeradwyaeth hon yn atgyfnerthu safle BitGo fel sylfaen sefydliadol ar gyfer y system ariannol fodern, gan gyfuno goruchwyliaeth ar lefel banc â'r diogelwch, y cydymffurfiaeth, a'r graddadwyedd sy'n diffinio seilwaith BitGo. O dan siarter y banc cenedlaethol, ac yn amodol ar
FIA, Formula 1 Group and All 11 Race Teams Officially Sign the Ninth Concorde Agreement, Securing Strength and Stability for the Sport in Pivotal Five-Year Agreement12.12.2025 17:10:00 CET | Press Release
The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, and Formula 1 Group, the Commercial Rights Holder, have today announced the signing of the Concorde Governance Agreement, a crucial contract defining the regulatory framework and governance terms of the FIA Formula One World Championship until 2030. This follows the announcement in March that the 2026 Commercial Concorde Agreement had been signed by all the teams and Formula 1 Group. Together, these agreements constitute the ninth Concorde Agreement, representing a major step forward in the professionalisation and global development of the sport. First introduced in 1981, the Concorde Agreements are designed to promote sporting fairness, technological innovation and operational excellence, and align all key stakeholders around a shared vision for structured governance and continued growth of the sport. Each iteration of the Concorde Agr
Anabranch Capital Management, LP supports relisting of SmartCraft ASA to Nasdaq Stockholm12.12.2025 16:26:00 CET | Press Release
Reference is made to the stock exchange announcement by SmartCraft ASA ("SmartCraft" or the "Company") on 1 December 2025 regarding the contemplated relisting of SmartCraft from Euronext Oslo Børs to Nasdaq Stockholm (the "Relisting") and the announcement of a cross-border merger to effect the Relisting. Funds managed by Anabranch Capital Management, LP (“Anabranch”) intend to vote in favour of the merger plan resolved by the boards of SmartCraft and its Swedish wholly owned subsidiary, SmartCraft Group AB (publ), to effect the Relisting at the Company's extraordinary general meeting planned for January 2025 (the "EGM"). Anabranch intends to vote with all Anabranch shares held at the Record Date for the EGM in favour of the relisting effected by the merger plan. Funds managed by Anabranch currently hold approximately 15.9 million shares in SmartCraft. Disclaimer: The views expressed are those of the authors and Anabranch Capital Management, LP as of the date referenced and are subject
Mohammed Ben Sulayem Re-Elected as President of the FIA12.12.2025 15:49:00 CET | Press Release
The Fédération Internationale de l’Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, today confirms that Mohammed Ben Sulayem has been re-elected as President of the FIA, following the election of his Presidential List by the General Assembly in Tashkent, Republic of Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251212213181/en/ President Mohammed Ben Sulayem now begins his second four-year term, having overseen a period of significant renewal and stabilisation for the organisation since his initial election in 2021. Over the past four years, the FIA has undergone a wide-ranging transformation, improving governance, operations and restoring the financial health of the federation. These changes have strengthened the FIA’s position as the world’s governing body for motorsport and the leading authority on safe, sustainable, and affordable mobility.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom